Posts Tagged ‘Christian Brander’

Categories

Posted in:

Thursday November 30th, 2017

IDIBAPS hosts the annual meeting of the European AIDS Vaccine Initiative (EAVI2020)

At the beginning of November, scientists from 22 institutions in Europe, Australia, Canada and the United States, which are part of the European AIDS Vaccine Initiative 2020 (EAVI2020), met in Barcelona to analyze the latest advances in the development of an effective vaccine against HIV within the framework of the European Research and Development Program Horizon 2020. The three Spanish centers participating in this consortium are the IDIBAPS, organizer of the meeting, the IrsiCaixa AIDS Research Institute and the Institute of Health Carlos III. In the context of the meeting a photo exhibition entitled “The development of an HIV vaccine in photos” was presented, with the aim of sharing the scientific advances at the community level. This exhibition can be visited at the Hospital Clínic of Barcelona until February 2018. Read the rest of this entry »

Comments Closed
Thursday November 10th, 2016

Scientists from the European AIDS Vaccine Initiative (EAVI2020) meet in Barcelona to analyze the results of the first year of the consortium

Scientists from 22 institutions in Europe, Australia, Canada and the United States meet in Barcelona on November 10-11 to discuss the trajectory and progress of the European AIDS Vaccine Initiative (EAVI2020). This initiative, funded by the European Commission with 23 million euro, started a year ago to accelerate the development of an effective vaccine against HIV. The three Spanish centers participating in the consortium are the IrsiCaixa AIDS Research Institute, which organizes the meeting in Barcelona, the IDIBAPS and the Institute of Health Carlos III. The participation of IrsiCaixa and IDIBAPS is part of HIVACAT, the Catalan research project for an AIDS vaccine.

Read the rest of this entry »

Comments Closed
Tuesday January 12th, 2016

Aelix Therapeutics gets €11.5M for therapeutic HIV vaccine

Aelix Therapeutics, a drug development company created from the HIVACAT project and specialized in the discovery and development of immunotherapies against HIV infection, has completed a funding round of €11.5 M. Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a syndicate of new investors including Johnson & Johnson Innovation – JJDC Inc. (“JJDC”), and Caixa Capital Risc, the venture capital division of Spain’s leading financial group, ‘la Caixa’. Doctors Josep M. Gatell, head of the Infectious Diseases Department at Hospital Clínic and IDIBAPS, Bonaventura Clotet and Christian Brander, from the Institute for AIDS Research (IrsiCaixa), and Jordi Naval, are co-founders of the company and in charge of this project.

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Monday November 02nd, 2015

IDIBAPS and IrsiCaixa participate in a 23 million euro project to develop HIV vaccine

IDIBAPS and the IrsiCaixa AIDS Research Institute participate in the European AIDS Vaccine Initiative (EAVI2020), a project to to accelerate the search for an effective HIV vaccine. This initiative, that is part of the European Comission framework programme for research and innovation (Horizon2020), brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA. IrsiCaixa and IDIBAPS are members of this consortium in which participate 22 institutions. Dr. Joan Joseph, researcher at the Infectious Diseases and AIDS IDIBAPS team led by Dr. Josep M. Gatell, will coordinate the project conducted at IDIBAPS over the next 5 years. At IrsiCaixa, an institute led by Dr. Bonaventura Clotet, this project will be coordinated by Dr. Christian Brander, head of the Host Cellullar and Genetic Immunity group and member of the consortium’s steering comitee. The other spanish participant in the consortium is the Instituto de Salud Carlos III.

Read the rest of this entry »

Comments Closed
Wednesday September 25th, 2013

Experts to report on advances in the search for the ultimate HIV prevention tool – a vaccine – at AIDS vaccine 2013

More than 500 research studies outlining the latest advances and obstacles in the search for an AIDS vaccine will be presented and debated at AIDS Vaccine 2013, the world’s only scientific meeting dedicated exclusively to HIV vaccine research. The conference, which runs Monday, 7 October through Thursday, 10 October, will bring more than 1,000 of the world’s leading vaccine researchers, funders and policy makers to the International Convention Center in Barcelona, Spain for four days of exchange, debate and direction-setting for the field.

AIDS Vaccine 2013 is organized by the Global HIV Vaccine Enterprise and by this year’s local conference hosts, the HIVACAT Program for HIV Vaccine Research, based in Barcelona. A vaccine that could help to stop the global HIV/AIDS epidemic is one of the most-sought-after goals of modern scientific research, and among the most complex scientific challenges ever undertaken.

Read the rest of this entry »

Comments Closed
Tuesday September 25th, 2012

HIVACAT has been licensed by the CSIC to develop a vaccine against HIV

hivacat

The HIVACAT program for the development of this vaccine today announced the obtention of a license to advance in the development of a possible vaccine against HIV —the virus that causes AIDS. The license includes a vaccine candidate called “MVA-B”, developed by researcher Mariano Esteban from the Spanish National Research Council (CSIC).

The agreement has been formalized by ESTEVE and the IrsiCaixa Institute for AIDS Research on behalf of HIVACAT. Research, however, will also be conducted at the Hospital Clínic de Barcelona —also part of the HIVACAT consortium.

The obtention of this license coincides with the first anniversary of the presentation in Madrid of very promising results on its efficacy as a preventive vaccine. These results were obtained in a study conducted jointly by the Hospital Clínic of Barcelona and the Gregorio Marañón Hospital of Madrid.

Read the rest of this entry »

Comments Closed
Page 1 of 212